Trial Profile
Effects of Blood Pressure Reduction on High Sensitivity C-Reactive Protein (hsCRP).
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Valsartan (Primary) ; Hydrochlorothiazide
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors Novartis
- 07 Nov 2011 Actual patient number is 1677 according to ClinicalTrials.gov.
- 07 Nov 2011 Actual end date (June 2005) added as reported by ClinicalTrials.gov.
- 06 Apr 2009 New trial record